The purpose of immune checkpoint inhibitors is to increase T lymphocytes’ immune response against tumor cells by blocking immunological checkpoint molecules like programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and programmed death ligand 1 (PD-L1). This evidence concerns the gene CTLA4 and neoplasm.